Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05407220 Not yet recruiting - Healthy Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

Start date: June 8, 2022
Phase: Phase 1
Study type: Interventional

A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

NCT ID: NCT05406050 Completed - Healthy Clinical Trials

Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects

Start date: October 20, 2020
Phase: Phase 1
Study type: Interventional

A single-center, open-label, randomized, two-period, crossover study design of pharmacokinetics and bioavailability in healthy Chinese subjects under fasting conditions.

NCT ID: NCT05405842 Not yet recruiting - Healthy Clinical Trials

Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis

AVNS
Start date: May 2023
Phase: N/A
Study type: Interventional

The goal of this study is to establish parameters of gastric myoelectrical activity and heart rate variability in healthy human subjects and compare and contrast them to those with gastroparesis and functional dyspepsia, at baseline and following taVNS.

NCT ID: NCT05403528 Withdrawn - Healthy Clinical Trials

Technology/Digital Media Use and Children's Word Learning Development

Start date: April 7, 2022
Phase: N/A
Study type: Interventional

The goal of this work is to address increasing concerns about young children's digital media exposure and language outcomes by testing how the times course of word learning unfolds in digital environments and the cascading impact of digital media on vocabulary outcomes. The findings will have important implications for understanding when and where optimal word learning from media can occur.

NCT ID: NCT05401227 Suspended - Healthy Clinical Trials

Glutamatergic Mechanisms: Aim2

Start date: October 15, 2022
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, and placebo controlled. 120 HV will be randomized to one of three ketamine arms, delivered in a bolus dose over one minute: low (0.086 mg/kg), medium (0.125 mg/kg), and high (0.23 mg/kg). Within each ketamine arm, subjects will be randomized to 4 days of TS-134 20 mg or placebo in a 5:3 ratio (25 TS-134:15 placebo). Following an outpatient Screening Period (up to 31 days), eligible subjects will undergo an up to 5-day inpatient Treatment Period. During the study, each subject will undergo a total of two ketamine sessions: a first session during the Screening Period and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart. All randomized subjects will be dosed with TS-134 or placebo daily in a fed state for 4 days during the study, titrated to 20 mg over the first 2 days.

NCT ID: NCT05400772 Not yet recruiting - Healthy Clinical Trials

Does Core Activation on an Unstable Surface Affect Periscapular Muscle Activation?

Start date: July 1, 2022
Phase:
Study type: Observational

The core muscles contain various muscle groups that stabilize the shoulders, pelvis, and spine, and they play an important role as pivot points in extremity movements. It is known that core muscles stabilize the lumbar region and core stabilization affects muscle activation. İn addition conscious abdominal muscle activation during exercise performance is believed to promote greater scapular muscle activation through existing myofascial connections. Studies support the relationship between the scapular region and the core region. Another aspect of rehabilitation is the use of unstable surfaces with exercise, since it is possible to increase neuromuscular demand without placing further overload on the musculoskeletal system. Hypothesis originating from the investigation: H1: Exercises performed with core activation on stable surfaces activate the muscles around the scapula more than exercises performed without core activation. H2: Exercises performed with core activation on unstable surfaces activate the muscles around the scapula more than exercises performed without core activation. H3: Exercises performed with core activation on unstable surfaces activate muscle activation around the scapula more than exercises performed on stable surfaces. H4: Exercises performed without core activation on unstable surfaces activate muscle activation around the scapula more than exercises performed on stable surfaces.

NCT ID: NCT05398146 Completed - Healthy Clinical Trials

The Effect of Three Methods Used in Reducing Pain During Dressing Change

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This randomized controlled study aims to determine the effect of listening to music (LM), ball squeezing (BS), and performing mathematical operations (MO) in reducing the pain experienced during the first dressing in children aged 8-18 with appendectomy.

NCT ID: NCT05397951 Recruiting - Healthy Clinical Trials

The Validation Study of Bioelectronics

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the safe wearability and basic functions of the multi-modality sensors fabricated in the PI lab.

NCT ID: NCT05397041 Completed - Healthy Clinical Trials

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Start date: June 6, 2022
Phase: Phase 1
Study type: Interventional

This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.

NCT ID: NCT05396742 Completed - Healthy Clinical Trials

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Start date: August 9, 2018
Phase: Phase 1
Study type: Interventional

The main objectives of this study were to estimate the absolute bioavailability of ravulizumab/rHuPH20 subcutaneous (SC) and to assess the safety and tolerability of ravulizumab/rHuPH20 SC.